Barclays’s aTyr Pharma ATYR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $35.2K | Sell |
45,123
-129,059
| -74% | -$109K | ﹤0.01% | 4430 |
|
|
2025
Q4 | $136K | Sell |
174,182
-167,177
| -49% | -$137K | ﹤0.01% | 4481 |
|
|
2025
Q3 | $246K | Buy |
341,359
+44,773
| +15% | +$203K | ﹤0.01% | 4199 |
|
|
2025
Q2 | $1.5M | Buy |
296,586
+59,495
| +25% | +$234K | ﹤0.01% | 3067 |
|
|
2025
Q1 | $716K | Buy |
237,091
+77,684
| +49% | +$283K | ﹤0.01% | 3299 |
|
|
2024
Q4 | $577K | Buy |
+159,407
| New | +$483K | ﹤0.01% | 3735 |
|
|
2024
Q2 | – | Sell |
-604,299
| Closed | -$1.18M | – | 5388 |
|
|
2024
Q1 | $1.18M | Buy |
604,299
+525,327
| +665% | +$916K | ﹤0.01% | 2985 |
|
|
2023
Q4 | $111K | Buy |
+78,972
| New | +$101K | ﹤0.01% | 4616 |
|
|
2019
Q2 | – | Sell |
-4
| Closed | – | – | 7348 |
|
|
2019
Q1 | $0 | Sell |
4
-1
| -20% | -$7 | ﹤0.01% | 7398 |
|
|
2018
Q4 | $0 | Hold |
5
| – | – | ﹤0.01% | 7421 |
|
|
2018
Q3 | $0 | Hold |
5
| – | – | ﹤0.01% | 7454 |
|
|
2018
Q2 | $0 | Hold |
5
| – | – | ﹤0.01% | 7363 |
|
|
2018
Q1 | $0 | Hold |
5
| – | – | ﹤0.01% | 7406 |
|
|
2017
Q4 | $0 | Hold |
5
| – | – | ﹤0.01% | 7181 |
|
|
2017
Q3 | $0 | Hold |
5
| – | – | ﹤0.01% | 7103 |
|
|
2017
Q2 | $0 | Hold |
5
| – | – | ﹤0.01% | 7001 |
|
|
2017
Q1 | $0 | Sell |
5
-404
| -99% | -$18.5K | ﹤0.01% | 7048 |
|
|
2016
Q4 | $12K | Buy |
409
+407
| +20,350% | +$16.7K | ﹤0.01% | 5841 |
|
|
2016
Q3 | $0 | Sell |
2
-65
| -97% | -$2.81K | ﹤0.01% | 6849 |
|
|
2016
Q2 | $3K | Buy |
67
+55
| +458% | +$2.56K | ﹤0.01% | 5879 |
|
|
2016
Q1 | $0 | Sell |
12
-21
| -64% | -$1.6K | ﹤0.01% | 6506 |
|
|
2015
Q4 | $4K | Buy |
33
+31
| +1,550% | +$4.41K | ﹤0.01% | 5633 |
|
|
2015
Q3 | $0 | Sell |
2
-61
| -97% | -$13.9K | ﹤0.01% | 7117 |
|
|
2015
Q2 | $16K | Buy |
+63
| New | +$19.6K | ﹤0.01% | 5817 |
|
Other funds holding ATYR
VCM
GCP
